MSKCC Oncology Fellow, Former Vanderbilt MSTP/UCLA Intern. Bass player in the CheckPoints. Physician-scientist studying metabolism. Views are my own! 🏳️🌈🩺
New in @jclinicalinvest: Digital cytometry across 10,000+ kidney, heart, lung & liver transplant biopsies reveals shared immune-cell signatures linked to rejection, advancing gene-expression monitoring and treatment tracking. jci.org/articles/view/208686#MMDx#TransplantResearch
🦉Cancer Immunotherapy: More Than 1,000 Antigen Candidates in Melanoma
A molecular atlas of cutaneous melanoma has revealed a substantial repertoire of potential immune targets, while exposing aspects of tumor biology that conventional genomic profiling may miss.
The study examined tumors from 183 patients using 13 molecular measurement layers, integrating genomic, transcriptomic, proteomic, immunopeptidomic, and metabolomic data.
Direct analysis of peptides presented for immune recognition identified more than 1,000 candidate tumor antigens. Protein modifications also revealed associations with immune activity and patient survival that were not apparent from protein abundance measurements alone.
The atlas offers a resource for antigen discovery, biomarker development, and future therapeutic research. However, identifying a presented peptide does not establish its immunogenicity or suitability as a safe vaccine or cellular-therapy target.
aacrjournals.org/cancerdisco…
A new study identifies B3GNT9 as a key engine of glioblastoma invasion, linking altered glycosylation and fatty acid metabolism to tumour spread.
nature.com/articles/s41388-0…
Congratulations to MSK's most recent awards and appointments, including @_Choi_Junhong on receiving a 2026 @NIH Director’s New Innovator Award; Dr. Gregory Goldgof and @juanosoriomd for being named Damon Runyon Clinical Investigators; Dr. Michael Postow on receiving a 2026 @CureMelanoma Breakthrough Consortium Pilot Translational Award; and more: bit.ly/48KVOgl
In a trial of the individualized neoantigen therapy intismeran in patients with resected stage IIB to IV melanoma, 24-month recurrence-free survival was 82.2% with intismeran–pembrolizumab and 70.0% with pembrolizumab alone. Full phase 3 INTerpath-001 trial results: nej.md/4sTuIgb
Editorial: Cancer Vaccines — From Treatment to Prevention nej.md/3UIPp1K
How do cancers emerge from healthy tissue? In @Nature today: leukaemia evolving in yearly blood samples up to 15 yrs before AML. First driver by age 20; each new driver multiplies growth 2–3×. A remarkably simple set of mathematical rules recapitulate it.
nature.com/articles/s41586-0…
📚 Recently wrote this piece for #ASCOConnection on learning during oncology fellowship—and how to keep building those skills beyond training.
A lot of it comes from advice I’ve picked up from mentors and attendings along the way, plus a few lessons from figuring out what has worked (and not worked) for me.
Hope it’s helpful to other fellows navigating the same process!
🔗 connection.asco.org/do/build…#MedEd#HemeOnc#OncTwitter
New NEJM trial of 1,880 people over 70:
Those who stopped their statins
12.7% had a heart attack, stroke or died
Compared to 9.2% who kept taking them
nejm.org/doi/full/10.1056/NE…